Pharmaceuticals

Vectibix (panitumumab) Market 2026 driven by targeted oncology therapy growth

March 27, 2026March 27, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Vectibix (panitumumab) Market In 2026 And What Value Is Projected For 2030?

The market for Vectibix (panitumumab) has shown robust expansion over the past few years. This market is projected to expand from $1.37 million in 2025 to $1.48 million in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. Key drivers of this historical growth include its approval for metastatic colorectal cancer, demonstrated effectiveness in EGFR inhibition, increasing adoption by oncology specialists, a rise in the incidence of colorectal cancer, and progress in targeted cancer therapies.

The market size for vectibix (panitumumab) is projected to experience substantial growth in the coming years. Its value is expected to ascend to $2 million by 2030, demonstrating a compound annual growth rate (CAGR) of 7.7%. This anticipated growth during the forecast period can be attributed to an increase in precision medicine adoption, enhanced cancer diagnostics, the expansion into further cancer therapies, rising oncology healthcare spending, and improved patient stratification. Key trends anticipated in the forecast period encompass a greater utilization of targeted EGFR therapies, the broadening of precision oncology treatments, a surge in biomarker-based patient selection, the adoption of hospital-based monoclonal antibodies, and the application of combination therapy for advanced cancers.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19944&type=smp

What Key Drivers Are Influencing The Growth Of The Vectibix (panitumumab) Market?

The vectibix (panitumumab) market is anticipated to grow as a result of the rising incidence of colorectal cancer. This type of cancer, which typically begins in the colon or rectum and often develops from precancerous polyps, is becoming more widespread due to unhealthy lifestyle choices such as a poor diet, insufficient exercise, and obesity, all of which contribute to an increased risk of polyp formation and cancer development. Vectibix (panitumumab) functions as a monoclonal antibody, targeting and inhibiting the epidermal growth factor receptor (EGFR), which helps slow tumor expansion and progression in patients with wild-type KRAS tumors, thereby providing an effective treatment alternative for those who have not responded to conventional chemotherapy. For example, the American Cancer Society, a US-based nonprofit organization, estimated 154,270 new colorectal cancer cases in February 2025, an increase from 152,810 cases in 2024. Therefore, the increasing prevalence of colorectal cancer is expected to fuel the growth of the vectibix (panitumumab) market.

What Are The Key Segments Of The Vectibix (panitumumab) Market?

The vectibix (panitumumab) market covered in this report is segmented –

1) By Distribution Channel: Hospital Pharmacies, Online Pharmacies

2) By Application: Colorectal Cancer Treatment, Other Cancer Treatments

3) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers

What Key Trends Are Influencing The Development Of The Vectibix (panitumumab) Market?

Leading companies operating in the vectibix (panitumumab) market are concentrating on developing advanced companion diagnostics to enable targeted therapies, enhance treatment efficacy, and ensure patient safety. These diagnostics are tests that supply crucial information for the safe and effective application of a corresponding therapeutic product. For instance, in October 2023, EntroGen Inc., a biotechnology company based in the U.S., obtained approval from the U.S. Food and Drug Administration (FDA) for the CRCdx RAS Mutation Detection Kit, serving as a companion diagnostic for Vectibix (panitumumab). The CRCdx RAS mutation detection kit represents a unique molecular diagnostic tool, signifying a major leap in precision medicine for colorectal cancer (CRC) patients. It is the first real-time PCR-based test in the U.S. to secure premarket approval (PMA) and completely fulfill the biomarker identification requirement for Vectibix. This innovative kit is engineered to precisely detect mutations in KRAS and NRAS exons 2, 3, and 4, providing high sensitivity and specificity. Its purpose is to allow clinicians to efficiently identify patients most likely to benefit from vectibix therapy, thereby minimizing unnecessary side effects and treatment costs.

Who Are The Leading Companies Operating In The Vectibix (panitumumab) Market?

Major companies operating in the vectibix (panitumumab) market are Amgen Inc.

Read the full vectibix (panitumumab) market report here:

https://www.thebusinessresearchcompany.com/report/vectibix-panitumumab-global-market-report-

Which Region Is Expected To Register The Fastest Growth In The Vectibix (panitumumab) Market?

North America was the largest region in the vectibix (panitumumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vectibix (panitumumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Vectibix (panitumumab) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19944&type=smp

Browse Through More Reports Similar to the Global Vectibix (panitumumab) Market 2026, By The Business Research Company

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Biologic And Biosimilar Ra Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologic-and-biosimilar-ra-drugs-global-market-report

Rheumatoid Arthritis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795